News

UVA teaming up with Charlottesville pharmaceutical company for new burn treatment

CHARLOTTESVILLE, Va. (WVIR) – The University of Virginia School of Medicine is teaming up with a Charlottesville company to create a new burn treatment.

Typically when skin is burned, the area surrounding it is impacted and dead, too. This new treatment is a cream that is put directly on severe wounds.

“Our hope is that by doing this, we can actually limit the amount of skin grafts people have to get and be able to treat especially like warfighters,” Doctor Mark Roeser said.

Roeser says the idea behind the drug comes from a type oflung treatment that is usually given in an IV. That form, however, is not convenient to treat burns.

“The time of injury is obviously the part of when you want to get the medication on you,” Roeser said. “So if it’s in a cream form, we can apply it more rapidly.”

Roeser is working with Charlottesville-based pharmaceutical company, Purnovate, which is a subsidiary of Adial, to make that happen.

“We’ve already done work to determine that our drugs seem to work well in skin penetration,” Adial CEO William Stilley said.

Stilley says his company has a history of working with UVA, which is why he and Roeser are taking this next step together.

“He’s going to take our molecules, put them into a cream, and then use them use that to try to develop something that would help him promote healing,” Stilley said.

“This will keep the burns limited to only the part, or at least try to limit to only the part that’s injured and not the part that your body enters either accidentally, or for whatever reason your body does that,” Roeser said.

The cream is supposed to reduce inflammation on burns.

“So much of the body’s damage can be caused by inflammation,” Stilley said. “And if we can have a good anti-inflammatory, there’s a number of different important diseases we can really help.”
The teams think if this works, it could be applied to other wounds, and be used in places where quick treatment counts, like war zones.

Read more here.

Recent News

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75